摘要
背景:在过去的几年里,DNA疫苗的免疫原性已经通过使用共刺激分子和分子佐剂来优化。据报道,包含炭疽毒素受体-1(ANTXR-1,别名TEM8,肿瘤内皮标记物8)的血管性血友病A(vWA / A)结构域的DNA序列的质粒(pATRex)佐剂通过诱导不溶性细胞内聚集体的形成。显然,由于聚集体形成促使小鼠骨质减少,我们面临着关于pATRex作为佐剂的安全性的不安的发现。 目的:本研究提供了关于骨髓内蛋白质佐剂作用的进一步证据,并对自身聚集蛋白佐剂对骨髓龛的免疫毒性提出质疑。 方法和结果:使用组织学,生物化学和蛋白质组学分析,我们阐明了骨髓龛内的pATRex效应,特别是我们证明细胞因子/趋化因子产生被破坏的再生障碍性样骨髓。 结论:上述发现为基于编码蛋白质聚集域的质粒的佐剂破坏骨髓元件的生理学特征提供了有力的支持。
关键词: 骨髓,骨髓龛,骨质减少症,DNA疫苗,佐剂,蛋白质聚集体。
Current Gene Therapy
Title:Molecular Adjuvants Based on Plasmids Encoding Protein Aggregation Domains Affect Bone Marrow Niche Homeostasis
Volume: 17 Issue: 5
关键词: 骨髓,骨髓龛,骨质减少症,DNA疫苗,佐剂,蛋白质聚集体。
摘要: Background: During last years, DNA vaccine immunogenicity has been optimized by the employment of co-stimulatory molecules and molecular adjuvants. It has been reported that plasmid (pATRex), encompassing the DNA sequence for the von Willebrand A (vWA/A) domain of the Anthrax Toxin Receptor-1 (ANTXR-1, alias TEM8, Tumor Endothelial Marker 8), acts as strong immune adjuvant by inducing formation of insoluble intracellular aggregates. Markedly, we faced with upsetting findings regarding the safety of pATRex as adjuvant since the aggregosome formation prompted to osteopenia in mice.
Objective: The present study provides additional evidences about the proteinaceous adjuvants action within bone marrow and questioned regarding the self-aggregation protein adjuvants immunotoxicity on marrow niches.
Methods & Results: Using histological, biochemical and proteomic assays we shed light on pATRex effects within bone marrow niche and specifically we evidenced an aplastic-like bone marrow with disrupted cytokine/chemokine production.
Conclusion: The above findings provide compelling support to the thesis that adjuvants based on plasmids encoding protein aggregation domains disrupt the physiological features of the bone marrow elements.
Export Options
About this article
Cite this article as:
Molecular Adjuvants Based on Plasmids Encoding Protein Aggregation Domains Affect Bone Marrow Niche Homeostasis, Current Gene Therapy 2017; 17 (5) . https://dx.doi.org/10.2174/1566523218666180105122626
DOI https://dx.doi.org/10.2174/1566523218666180105122626 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Progress in Syntheses of 3-n-Butylphthalide and Its Analogues
Current Organic Chemistry Which Drugs for the Control of Fever in Critical Patients
Current Drug Targets Peroxisome Proliferator Activated Receptor α Ligands as Anticancer Drugs Targeting Mitochondrial Metabolism
Current Pharmaceutical Biotechnology Doxorubicin vs. ladirubicin: methods for improving osteosarcoma treatment
Mini-Reviews in Medicinal Chemistry Increased Exercise Favorably Modifies Coronary Artery Disease and Peripheral Arterial Disease Outcomes
Current Vascular Pharmacology Small Ruminant Lentiviruses and Human Immunodeficiency Virus: Cousins that Take a Long View
Current HIV Research Antiviral Therapy Targeting Viral Polymerase
Current Pharmaceutical Design Epigenetic Regulation of Epithelial to Mesenchymal Transition
Current Cancer Drug Targets Muscle Metabolism and Exercise Capacity in Cachexia
Current Pharmaceutical Design microRNA Biogenesis Pathway as a Therapeutic Target for Human Disease and Cancer
Current Pharmaceutical Design Structural Organization of the Regulatory Domain of Human 5- Lipoxygenase
Current Protein & Peptide Science Assessment of Anti-inflammatory Activity of 3-Acetylmyricadiol in LPSStimulated Raw 264.7 Macrophages
Combinatorial Chemistry & High Throughput Screening Neurotrophic Factors in Parkinson’s Disease: What Have we Learned from Pre-Clinical and Clinical Studies?
Current Medicinal Chemistry The IFN-λ Family (IL-28/29)
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Cellular and Physiological Effects of Short-Chain Fatty Acids
Mini-Reviews in Medicinal Chemistry Neurokinin-1 Receptor Antagonists in Lung Cancer Therapy
Letters in Drug Design & Discovery Protein N-Glycosylation in the Baculovirus-Insect Cell System
Current Drug Targets Role of microRNAs in Non-Alcoholic Steatohepatitis
Current Pharmaceutical Design Redox Active Iron at the Center of Oxidative Stress in Alzheimer Disease
Letters in Drug Design & Discovery Microdialysis in Drug Discovery
Current Drug Discovery Technologies